Psych Capital PLC - Board Resignation, Role Change and Option Grant
Announcement provided by
Shortwave Life Sciences Plc · PSY05/04/2024 14:00
5 April, 2024
PSYCH CAPITAL PLC
("Psych Capital", or "the Company")
William Potts Board Resignation and Role Change to Strategic Adviser
Share Options Grant
William Potts commented: "It has been a pleasure to have worked with the exceptional team at Psych Capital over the years and I would like to thank them all for their hard work and dedication. I look forward to supporting Psych Capital during this exciting time to become a leader in Psychedelic science and healthcare."
Rivki Stern, Chief Executive Officer of the Company, stated: "William Potts has been instrumental in the building of Psych Capital and the implementation of its strategy and value proposition. We will continue to rely on William's strategic advice as we reaffirm our Company's commitment to supporting and developing pivotal treatments for mental health."
Grant of Share Options
The Company further announces that it has granted share options over ordinary shares of the Company, as part of the unapproved share option scheme, to its former chairman, Joseph Colliver, in recognition for the uncompensated work done by him leading up to the acquisition of Shortwave Pharma Inc,. The options grant was decided upon at the time of completion of the acquisition in November last year.
50,000 share options will be granted under the existing share option scheme with effect from 4 April 2024 and will be capable of being exercised for a period of 2 years. The exercise price is
The directors of the Company accept responsibility for the contents of this announcement.
Enquiries:
Company:
Rivki Stern: +972 54 762 1621
info@psych.capital
Peterhouse Capital Limited:
Corporate Adviser:
Guy Miller /Narisha Ragoonanthun: + 44 (0) 20 7469 0930
Corporate Broker
Lucy Williams: +44 (0) 20 7469 0930
Duncan Vasey: +44 (0) 20 7220 9797 (Direct)
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.